Healthcare, industrials and autos the big laggards ahead of US tariffs announcement; defensives outperform:
Savara completes submission of the BLA to the FDA for MOLBREEVI as a treatment for autoimmune pulmonary alveolar Proteinosis (aPAP) ($2.70, 0.00)
Powered by FactSet Research Systems Inc.